Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    WRAIR Begins Ebola Vaccine Phase 2 Trial

    By Global Biodefense StaffJanuary 6, 2016
    WRAIR Ebola Clinical Trial
    A new Ebola vaccine regimen is being tested at the Clinical Trial Center in Silver Spring, Md. Credit: WRAIR
    Share
    Facebook LinkedIn Reddit Email

    The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected study volunteers.

    This study includes two vaccine candidates, Ad26.ZEBOV from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo from Bavarian Nordic, which will be given sequentially as a “prime boost” regimen.

    In September 2015, Crucell was awarded $28.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to help accelerate the development of its investigational Ebola prime-boost vaccine regimen.

    Seventy-five volunteers will receive a prime dose with MVA-BN-Filo followed by a boost with Ad26.ZEBOV at the WRAIR Clinical Trials Center in Silver Spring, Md. Early next year, WRAIR-affiliated sites in Africa will also begin evaluating this regimen, as well as a vaccination schedule beginning with Ad26.ZEBOV and then boosted with MVA-BN-Filo.

    See also: Bavarian Nordic Announces Start of EBOVAC-Salone Trial for Ebola Vaccine

    Researchers will assess the safety and tolerability of the vaccine schedules and characterize the immune response, which should help them better understand these different regimens. Janssen and other development partners have generated preliminary data from a small group of healthy subjects demonstrating that both regimens were safe and immunogenic.

    The study will strengthen safety and immunogenicity evidence of the regimens in healthy subjects and extend the population studied in Phase 1 to include volunteers up to and including 70 years of age and volunteers with stably suppressed HIV-infection.

    “It is critical that we know these vaccines are safe and immunogenic in the communities where they will be used in Africa,” said Lt. Col. Julie Ake, an infectious disease physician, U.S. Military HIV Research Program (MHRP) Principal Deputy and protocol chair for the international study.

    The study includes HIV-infected volunteers because they represent some of those who might benefit from a preventive Ebola vaccine in Africa. “It’s an important consideration given that both of these viruses can be present in the same communities,” said Col. Nelson Michael, MHRP Director.

    See also: DTRA Awards 8M for Ebola Medical Countermeasure

    This clinical trial is a collaboration between WRAIR and Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, with funding from the Joint Vaccines Acquisition Program at the Department of Defense’s Joint Program Executive Office for Chemical and Biological Defense.

    Initially conducted at WRAIR in Silver Spring, Md., the study will expand to six sites in Africa in early 2016. Approximately 575 volunteers will participate in total. It will be conducted at clinical research sites affiliated with WRAIR’s Military HIV Research Program in Nigeria, Uganda, Kenya, Tanzania and Mozambique.

    This is the second Ebola vaccine clinical trial conducted at WRAIR, and will be the fourth Ebola vaccine study conducted in Africa by the Institute and MHRP.

    “Infectious diseases such as Ebola pose a significant threat to the U.S. Military and the global community,” said Col. Stephen Thomas, WRAIR’s Deputy Commander of Operations. “WRAIR has extensive expertise in infectious diseases and an international research network in countries where diseases are endemic, giving us an ideal platform to conduct these types of studies.”

    ASPR BARDA Ebola Emerging Threats HHS Vaccine News WRAIR
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleForensic Tools for Bioterrorism Events
    Next Article Protocols for Treating Children Infected with Ebola

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Valley Fever: An Invisible Killer Expands Its Range in the American West

    November 17, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.